The short version of WADA prohibited list fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-24. Anything still debated is marked as such rather than presented as settled.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
This has been supported by several organizations, including the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, the Heffter Research Institute, and the Albert Hofmann Foundation, which exist to fund, encourage, and coordinate research into the medicinal and spiritual uses of LSD and related psychedelics. New clinical LSD experiments in humans started in 2009 for the first time in 35 years. As the drug is illegal in many areas of the world, potential medical uses have historically been difficult to study. Investigational uses of LSD include the treatment of alcoholism, anxiety, and depression, among other conditions. Another use is alleviation of anxiety in terminally ill cancer patients. A single dose of LSD may temporarily reduce alcohol abuse and some psychiatric symptoms, but evidence is limited and unreliable due to methodological flaws and unclear causation. In 2024, the FDA designated a form of LSD as a breakthrough therapy to treat generalized anxiety disorder which is being developed by MindMed. A study published by the Journal of the American Medical Association in September, 2025 explored the optimal dose of LSD to lower patients' anxiety. The study was conducted by the pharmaceutical company MindMed. The researchers compared how LSD doses of 25 μg, 50 μg, 100 μg, 200 μg, or placebo impacted anxiety scores among study participants. The results of the study found that 100 μg was the optimal dose to reduce anxiety among the studied patients.
Merocyanines are a class of polymethine dyes. They include quinophthalones and spiropyrans. which are clearly defined by set structural properties. Merocyanines belong to the group of dyes referred to as functional dyes, where their applications are not only determined by their colour, but also their valuable chemical properties. These dyes are usually intensely colored and have large extinction coefficients. Merocyanine 540 was the first fluorescent dye used for measuring membrane potential, while Brooker's merocyanine and related compounds are notable for their solvatochromatic properties.
=== Seizures === For drug-resistant focal epilepsy, pregabalin is useful as an add-on therapy to other treatments. Its use alone is less effective than some other seizure medications. It is unclear how it compares to gabapentin for this use.
== Interactions == Acidifying agents: Drugs or foods that acidify the urine, such as ascorbic acid, increase urinary excretion of dextroamphetamine, thus decreasing the half-life and effectiveness of dextroamphetamine in the body. Alkalinizing agents: Drugs or foods that alkalinize the urine, such as sodium bicarbonate, decrease urinary excretion of dextroamphetamine, thus increasing the half-life and effectiveness of dextroamphetamine in the body. CYP2D6 inhibitors: Hydroxylation via the cytochrome P450 enzyme CYP2D6 is the major pathway of metabolism of dextroamphetamine. Potent CYP2D6 inhibitors, such as paroxetine, fluoxetine, bupropion, and duloxetine, among others, may inhibit the metabolism of dextroamphetamine and thereby increase exposure to it. Studies characterizing this potential interaction are currently lacking. Concomitant use of lisdexamphetamine with CYP2D6 inhibitors may increase the risk of serotonin syndrome due to greater drug exposure. Monoamine oxidase inhibitors: Concomitant use of MAOIs and central nervous system stimulants such as lisdexamphetamine can cause a hypertensive crisis. Norepinephrine reuptake inhibitors (NRIs) like atomoxetine prevent norepinephrine release induced by amphetamines and have been found to reduce the stimulant, euphoriant, and sympathomimetic effects of dextroamphetamine in humans.
== Properties == Potassium arsenite is an inorganic salt that exists as an odorless white solid. It is largely soluble in water and only slightly soluble in alcohol. Solutions of potassium arsenite contain moderate concentrations of hydroxide, and are thus slightly basic. While potassium arsenite is noncombustible, heating it results in its decomposition and the formation of toxic fumes that include arsine, arsenic oxides, and potassium oxides. Potassium arsenite also reacts with acids to yield toxic arsine gas. The structure was determined by X-ray crystallography. As found for related As(III) compounds, the arsenic is pyramidal. The [AsO3]− subunits are connected by two bridging oxides.
Sources: en.wikipedia.org
== Contraindications == Methylergometrine is contraindicated in patients with hypertension and pre-eclampsia. It is also contraindicated in HIV positive patients taking protease inhibitors, delavirdine, and efavirenz (which is also an agonist at the 5-HT2A–mGlu2 receptor protomer and increases the chances of a patient experiencing hallucinations during methylergometrine therapy).
The 2021 edition of Fastlane would be the beginning of WWE phasing out the standalone WWE Network, with the company partnering with other platforms to distribute its content. Beginning with that edition of Fastlane in the United States, events began airing on NBCUniversal's streaming service, Peacock, following a merger of the American WWE Network under Peacock in March that year. The standalone version of the American WWE Network shut down on April 4. Over the next couple of years, other countries would see their own version of the WWE Network merge under other services. In Indonesia, the WWE Network merged under Disney+ Hotstar in January 2022, followed by a merger under Disney+ in the Philippines in November that year, while in Australia, it merged under Binge in January 2023 and then Abema in Japan that October. With this increased emphasis of digital platforms over traditional PPV outlets, WWE began to refer to all PPV and livestreaming events as "Premium Live Events" (PLEs), starting with the Day 1 event on January 1, 2022. In January 2025, the majority of the countries that still had the WWE Network merged under Netflix, with only a small number of countries maintaining the WWE Network due to pre-existing contracts. Beginning with Wrestlepalooza in September 2025, ESPN's direct-to-consumer streaming service assumed the streaming rights for main roster PLEs in the United States as part of a five-year deal following WWE's contract with Peacock. Also as part of the deal, select events also air on ESPN's linear channels.
Source 2 has also been used for Valve's Artifact and Dota Underlords, with the engine later being supported on Android and iOS for the latter. The engine also supports the creation of games in virtual reality, being used in SteamVR Home, the Robot Repair tech demo within The Lab, and Half-Life: Alyx. Source 2 tools made specifically for creating content for Half-Life: Alyx were released in May 2020.
K2CO3 + CO2 + H2O → 2 KHCO3 CO2 de-scrubber: The above potassium carbonate solution (enriched with CO2) is then sent to the CO2 de-scrubber where CO2 is de-scrubbed by stepwise (usually two steps) flashing. The first step is done to remove the hydrocarbon gases, and the second step is employed to strip off CO2.
Sources: en.wikipedia.org
== Scientific references == Aller, Raymond D.; Salazar, Vincent (2016), "Microbiology Laboratory Information Systems", Manual of Commercial Methods in Clinical Microbiology, John Wiley & Sons, Inc, pp. 377–385, doi:10.1002/9781119021872.ch20, ISBN 978-1-119-02187-2 Burkhartsmeier, Gary (June 2007), "HIPAA: Where are we now", Research Gate, vol. 39, no. 6, p. 28, PMID 17691704 De Rienzo, Assunta; Cook, Robert W.; Wilkinson, Jeff; Gustafson, Corinne E.; Amin, Waqas; Johnson, Clare E.; Oelschlager, Kristen M.; Maetzold, Derek J.; Stone, John F.; Feldman, Michael D.; Becich, Michael J.; Yeap, Beow Y.; Richards, William G.; Bueno, Raphael (2017-01-01), "Validation of a Gene Expression Test for Mesothelioma Prognosis in Formalin-Fixed Paraffin-Embedded Tissues", The Journal of Molecular Diagnostics, 19 (1): 65–71, doi:10.1016/j.jmoldx.2016.07.011, PMC 5225306, PMID 27863259 Turgeon, Mary Louise (2015-02-10), "Linne & Ringsrud's Clinical Laboratory Science - E-Book: The Basics and Routine Techniques", Elsevier Health Sciences, ISBN 978-0-323-37061-5 "Association of Pathology Chairs", Academic Pathology. 5: 2374289518788096, vol. 5, 2018-07-09, doi:10.1177/2374289518788096, ISSN 2374-2895, PMC 6039897
Alexander Butlerov showed in 1861 that the formose reaction created sugars including tetroses, pentoses, and hexoses when formaldehyde is heated under basic conditions with divalent metal ions like calcium. R. Breslow proposed that the reaction was autocatalytic in 1959.
Chinese production mainly trades with and profits from North America. In 2002, they were seeking to expand through eastern United States. In the post 9/11 era, trading between borders became difficult and because new international laws were set into place, the opium trade became more diffused. Power shifted from remote to high-end smugglers and opium traders. Outsourcing became a huge factor for survival for many smugglers and opium farmers. In 2023 Burma overtook Afghanistan and became the world's largest producer of opium, producing 1,080 metric tons according the UN Southeast Asia Opium Survey report.
== History == Polatuzumab vedotin was discovered by a team at Genentech led by Dan Eaton, Fred de Sauvage, and Andy Polson, who had been trying to develop ADCs for solid tumors without success, and in 2002 turned to blood cancers. In June 2019, polatuzumab vedotin was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product, to treat adults with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma. The US Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product. The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567) that was conducted in the United States, Canada, Europe, and Asia. Participants in the trial had lymphoma that came back or did not improve after prior treatment. The FDA granted the application of polatuzumab vedotin breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Polivy to Genentech. Polatuzumab vedotin was approved for medical use in the European Union in January 2020, as a second-line treatment. The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018.
===== Response to stimuli ===== Serotonin is important in environmental response pathways, along with other neurotransmitters. Specifically, it has been found to be involved in auditory processing in social settings, as primary sensory systems are connected to social interactions. Serotonin is found in the IC structure of the midbrain, which processes specie specific and non-specific social interactions and vocalizations. It also receives acoustic projections that convey signals to auditory processing regions. Research has proposed that serotonin shapes the auditory information being received by the IC and therefore is influential in the responses to auditory stimuli. This can influence how an organism responds to the sounds of predatory or other impactful species in their environment, as serotonin uptake can influence aggression or social interaction.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.